ZDA
XBI icon

Zweig-DiMenna Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Zweig-DiMenna Associates’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-110,700
Closed -$13.5M – 100
2025
Q4 		$13.5M Buy
+110,700
New +$12.7M 0.84% 37

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Zweig-DiMenna Associates's XBI Position: Q1 2026 in Review

Zweig-DiMenna Associates sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 110,700 shares — an estimated $13.5M sold.

Zweig-DiMenna Associates first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $13.5M in Q4 2025. 816 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Zweig-DiMenna Associates reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 110,700 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $13.5M.
  • Zweig-DiMenna Associates first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
  • Zweig-DiMenna Associates's State Street SPDR S&P Biotech ETF position peaked at $13.5M in Q4 2025.
  • 816 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2026, filed 5 May 2026.